Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 9:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo dose Clear all
Recruiting Phase 4 Interventional

Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder

NCT06269627
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Acamprosate calcium, Placebo
Drug · Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 24, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)

NCT00595413
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo matched to atacicept, Atacicept: with loading dose, Atacicept, Adalimumab
Drug · Biological
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 24, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)

NCT00365859
View directory record Official record
Conditions
Autistic Disorder, Behavioral Symptoms
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
55
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 24, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).

NCT00768079
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Benralizumab
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Tampa, Florida • Springfield, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Sep 24, 2026, 9:32 PM EDT
Recruiting Early Phase 1 Interventional

Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder

NCT06582888
View directory record Official record
Conditions
Nicotine Addiction, Craving
Interventions
Varenicline Tartrate, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
22 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 24, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair

NCT01920594
View directory record Official record
Conditions
Surgical Procedures
Interventions
GSK1278863, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 24, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of a Kappa Agonist on Hot Flashes in Menopausal Women

NCT02070718
View directory record Official record
Conditions
Treatment of Menopausal Hot Flashes
Interventions
Standard Dose Kappa Agonist, Half Dose Kappa Agonist, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Sep 24, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effects of SAMe in Patients With Alcoholic Liver Disease

NCT00573313
View directory record Official record
Conditions
Liver Disease, Alcoholic
Interventions
S-adenosylmethionine, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
21 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 24, 2026, 9:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Epsilon Aminocaproic Acid (EACA) for the Reduction of Blood Loss in Total Hip Arthroplasty (THA)

NCT01391182
View directory record Official record
Conditions
Degenerative Joint Disease, Osteoarthritis
Interventions
EACA, Placebo arm
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Sep 24, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

NCT04142424
View directory record Official record
Conditions
Metabolic Disorders, Non-alcoholic Steatohepatitis
Interventions
AZD2693, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 24, 2026, 9:32 PM EDT
Completed Phase 2 Interventional

Double Blind Trial in Children With Autism Spectrum Disorder

NCT06058962
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Suramin Sodium
Drug
Lead sponsor
Paxmedica
Industry
Eligibility
4 Years to 17 Years · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 24, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Antidepressants in Chronic Back Pain

NCT00964886
View directory record Official record
Conditions
Back Pain
Interventions
cognitive behavioral therapy, desipramine hydrochloride, benztropine mesylate 0.125 mg daily
Behavioral · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 24, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

NCT01514461
View directory record Official record
Conditions
Familial Chylomicronemia Syndrome (FCS)
Interventions
LCQ908, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Seatlle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 24, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

NCT01454986
View directory record Official record
Conditions
Healthy
Interventions
ALXN1007, Placebo
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Sep 24, 2026, 9:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Testosterone Replacement in Older Men and Atherosclerosis Progression

NCT00287586
View directory record Official record
Conditions
Hypogonadism, Atherosclerosis
Interventions
Testosterone Gel (Androgel), Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
60 Years and older · Male only
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
3
States / cities
Phoenix, Arizona • Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Sep 24, 2026, 9:32 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT07363694
View directory record Official record
Conditions
Moderate to Severe Chronic Obstructive Pulmonary Disease
Interventions
PF-07275315 dose 1, PF-07275315-dose 2, Placebo, PF-07275315-dose 3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 80 Years
Enrollment
1,156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
61
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 24, 2026, 9:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fiber Metabolism in Chronic Obstructive Pulmonary Disease

NCT04459156
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Aging
Interventions
Fiber Inulin, Placebo Maltodextrin
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 24, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

NCT02605174
View directory record Official record
Conditions
Migraine With or Without Aura
Interventions
Lasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
3,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
95
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2019 · Synced Sep 24, 2026, 9:32 PM EDT
Completed Phase 4 Interventional Results available

Effect of Low Dose Corticosteroids on Perioperative Markers of Thrombosis and Fibrinolysis in Total Knee Arthroplasty

NCT01815918
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Hydrocortisone, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 24, 2026, 9:32 PM EDT
Recruiting Phase 1 Interventional

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

NCT07305818
View directory record Official record
Conditions
Graves Disease
Interventions
MER511 (IV), Placebo comparator (IV), MER511 (SC), Placebo comparator (SC), MER511 (SC) for MAD, Placebo comparator (SC) for MAD
Biological
Lead sponsor
Merida Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
Torrance, California • Hollywood, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 24, 2026, 9:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tolerance and Utilization of Agave Inulin in Healthy Adults

NCT01925560
View directory record Official record
Conditions
Tolerance
Interventions
Agave Inulin, Placebo
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
20 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 24, 2026, 9:32 PM EDT
Not listed Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19

NCT04469179
View directory record Official record
Conditions
COVID-19, SARS-CoV2
Interventions
SAB-185, Normal Saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Miami Beach, Florida • Omaha, Nebraska • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 24, 2026, 9:32 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Once Versus Twice Daily Iron Supplementation in Pregnant Women

NCT02839096
View directory record Official record
Conditions
Anemia in Pregnancy
Interventions
Placebo, Ferrous Sulfate
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 24, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Results available

A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis

NCT02780388
View directory record Official record
Conditions
Adult Onset Rheumatoid Arthritis
Interventions
VIB4920, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Anniston, Alabama • DeBary, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 24, 2026, 9:32 PM EDT